Rchr
J-GLOBAL ID：201801015550309195   Update date: Feb. 01, 2024

Ishibashi Mariko

Ishibashi Mariko
Affiliation and department：
Nippon Medical School Department of Microbiology and Immunology

About Nippon Medical School Department of Microbiology and Immunology


Job title： senior assistant professor
Research field  (4)： Molecular biology ,  Tumor biology ,  Immunology ,  Hematology and oncology
Research keywords  (7)： Hematopoietic malignancy ,  免疫関連分子 ,  Molecular Oncology ,  Molecular biology ,  immune checkpoint ,  Cancer ,  Tumor microenvironment
Research theme for competitive and other funds  (17)：
  • 2022 - 2025 骨髄微小環境におけるSiglec-15を介した多発性骨髄腫の病態進展機序の解明
  • 2020 - 2025 Whole gamma imaging to break through the physical limitation of positron emission tomography
  • 2023 - 2024 多発性骨髄腫における抑制型樹状細胞の解明とその克服に向けて
  • 2023 - 2024 多発性骨髄腫における免疫抑制性腫瘍微小環境の改善に向けて
  • 2022 - 2023 低pH骨髄腫微小環境に起因した腫瘍関連マクロファージの誘導機序の解明
Show all
Papers (25)：
  • Mariko Ishibashi, Miwako Takahashi, Taiga Yamaya, Yoichi Imai. Current and Future PET Imaging for Multiple Myeloma. Life. 2023. 13. 8. 1701-1701
  • Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, et al. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental hematology. 2023
  • Wataru Nakajima, Kai Miyazaki, Masahiro Sakaguchi, Yumi Asano, Mariko Ishibashi, Tomoko Kurita, Hiroki Yamaguchi, Hiroyuki Takei, Nobuyuki Tanaka. Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers. 2022. 14. 1. 248-248
  • Yasuko Kuribayashi-Hamada, Mariko Ishibashi, Atsushi Tatsuguchi, Toshio Asayama, Namiko Takada-Okuyama, Asaka Onodera-Kondo, Keiichi Moriya, Takehito Igarashi, Hiroyuki Onose, Sakae Tanosaki, et al. Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma. Journal of Nippon Medical School. 2022. 89. 3. 301-308
  • Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, Hideto Tamura. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells. Molecular Cancer Therapeutics. 2021. 20. 7. 1283-1294
ｍore...
MISC (27)：
  • 田村 秀人, 石橋 真理子, 高橋 秀実, 猪口 孝一. Novel Therapeutic Targets on the Surface of Myeloma Cells in Association with Marrow Microenvironment 多発性骨髄腫におけるSLAMファミリー分子を標的とした治療. 臨床血液. 2020. 61. 7. 818-826
  • 田村秀人, 石橋真理子, 高橋秀実, 猪口孝一. SLAM family proteins as therapeutic targets in multiple myeloma. 臨床血液. 2020. 61. 7
  • Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, et al. Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. BLOOD. 2019. 134
  • 砂川 実香, 石橋 真理子, 海渡 裕太, 木下 量介, 朝山 敏夫, 守屋 慶一, 半田 寛, 佐々木 純, 今井 陽一, 田中 紀奈, et al. 血清KL-6値は多発性骨髄腫の予後予測因子となりうる(KL-6 may be an excellent predictor of prognosis in multiple myeloma). International Journal of Myeloma. 2019. 9. 1. 86-86
  • 添田 沙織, 山下 卓也, 磯田 淳, 鈴木 一史, 木口 亨, 田中 紀奈, 田中 淳司, 佐々木 純, 小松 則夫, 安井 寛, et al. 実臨床における再発・難治性骨髄腫患者に対するERd療法の効果(Efficacy of elotuzumab plus lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma in the real-world practice setting). International Journal of Myeloma. 2019. 9. 1. 146-146
ｍore...
Books (4)：
  • Bone marrow immune microenvironment in pathogenesis of multiple myeloma
    2023
  • 骨髄腫とインフラマソーム
    科学評論社 臨床免疫・アレルギー科 2022
  • 多発性骨髄腫におけるanti-BCMA CAR-T療法
    科学評論社 血液内科 2019
  • Expression and function of signaling lymphocytic activation molecule (SLAM) family molecules in multiple myeloma
    2017
Lectures and oral presentations  (56)：
  • The multiple myeloma microenvironment triggers inflammasome activation in tolerogenic dendritic cells to promote disease progression
    (第55 日本免疫学会学術集会 2024)
  • Tolerogenic dendritic cells alter the immune microenvironment in multiple myeloma.
    (2023)
  • 多発骨髄腫の治療戦略の確立に向けて 免疫微小環境を理解する
    (Multiple Myeloma Web Seminar (ブリストルマイヤーズ招待講演) 2023)
  • Characteristics of tolerogenic dendritic cells in multiple myeloma microenvironment.
    (第81回日本癌学会学術集会 2023)
  • 多発性骨髄腫の免疫微小環境
    (2023)
ｍore...
Professional career (1)：
  • 理学博士
Work history (4)：
  • 2022/10 - 現在 日本医科大学大学院 微生物学・免疫学 講師
  • 2022/10 - 現在 Nippon Medical School Department of Microbiology and Immunology
  • 2017/10 - 2022/09 Nippon Medical School Department of Microbiology and Immunology Research associate/ Assistant professor
  • 2010/04 - 2017/09 Nihon Medical School Department of Hematology postdoctoral fellow
Committee career (2)：
  • 2019/05 - 現在 日本骨髄腫学会 代議員
  • 2021 - 日本骨髄腫学会 第46回学術集会 プログラム委員
Awards (9)：
  • 2022/05 - 19th International Myeloma Workshop Travel Award
  • 2022/05 - 日本骨髄腫学会 プレナリー演題賞
  • 2021/09 - 日本医科大学 丸山記念研究助成
  • 2021/05 - 12th JSH International Symposium best poster award APRIL Upregulation in Myeloma Cells by Immunomodulatory Drugs Promotes Aggressive Myeloma.
  • 2021 - 日本私立学校振興・共済事業団 若手研究者奨励賞
Show all
Association Membership(s) (4)：
THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  THE JAPANESE SOCIETY OF MYELOMA ,  THE JAPANESE SOCIETY OF HEMATOLOGY ,  Japanese Cancer Association
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM